Citation Impact
Citing Papers
New β-Lactam–β-Lactamase Inhibitor Combinations
2020
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
2018
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review
2023 Standout
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <em>Enterobacteriaceae</em>
2018
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
2019 Standout
Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy
2017
Treatment of Infections Due to MDR Gram-Negative Bacteria
2019
Development and Research Progress of Anti-Drug Resistant Bacteria Drugs
2021
Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology
2020
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
2019
Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter
2020
<p>Antimicrobial Resistance: Implications and Costs</p>
2019 Standout
Bacterial Antibiotic Resistance: The Most Critical Pathogens
2021 Standout
The role of new β-lactamase inhibitors in gram-negative infections
2019
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae
2018
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Works of Amanda Paschke being referenced
The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study
2020
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
2017
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
2019
1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections
2020
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
2016